Core Insights - Zoetis (ZTS) stock is noteworthy due to its high margins, indicating strong pricing power and cash generation capabilities, currently available at a discounted price [2][3] Financial Performance - Revenue growth for Zoetis was 5.3% over the last twelve months and averaged 5.5% over the past three years, indicating stable but not rapid growth [8] - The company reported an operating cash flow margin of approximately 31.2% and an operating margin of 37.5% for the last twelve months [8] - Long-term profitability metrics show an operating cash flow margin of about 28.7% and an average operating margin of 36.6% over the past three years [8] - ZTS stock is currently trading at a price-to-sales multiple of 6.8, reflecting a 24% discount compared to one year ago [8] Market Position - Zoetis provides a range of medicines, vaccines, and diagnostic products for animal health, targeting various livestock species to prevent diseases affecting respiratory, gastrointestinal, and reproductive systems [4]
Buy Zoetis Stock Today?